Interestingly, we found that anagliptin (a dipeptidyl peptidase 4 inhibitor) also decreased the level of FABP4 in serum and synovial macrophages in an RA mouse model,53 which alleviated the severity of RA. This evidence concerns the gene FABP4 and rheumatoid arthritis.